369 related articles for article (PubMed ID: 32198022)
21. Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs.
Notenboom S; Weigand KM; Proost JH; van Lipzig MMH; van de Steeg E; van den Broek PHH; Greupink R; Russel FGM; Groothuis GMM
Eur J Pharm Sci; 2018 Mar; 115():175-184. PubMed ID: 29309877
[TBL] [Abstract][Full Text] [Related]
22. Prediction of the Clinical Risk of Drug-Induced Cholestatic Liver Injury Using an In Vitro Sandwich Cultured Hepatocyte Assay.
Susukida T; Sekine S; Nozaki M; Tokizono M; Ito K
Drug Metab Dispos; 2015 Nov; 43(11):1760-8. PubMed ID: 26329788
[TBL] [Abstract][Full Text] [Related]
23. Development of a Battery of
Rathman J; Yang C; Ribeiro JV; Mostrag A; Thakkar S; Tong W; Hobocienski B; Sacher O; Magdziarz T; Bienfait B
Chem Res Toxicol; 2021 Feb; 34(2):601-615. PubMed ID: 33356149
[TBL] [Abstract][Full Text] [Related]
24. Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI).
Minerali E; Foil DH; Zorn KM; Lane TR; Ekins S
Mol Pharm; 2020 Jul; 17(7):2628-2637. PubMed ID: 32422053
[TBL] [Abstract][Full Text] [Related]
25. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Aleo MD; Luo Y; Swiss R; Bonin PD; Potter DM; Will Y
Hepatology; 2014 Sep; 60(3):1015-22. PubMed ID: 24799086
[TBL] [Abstract][Full Text] [Related]
26. Prediction of drug-induced liver injury and cardiotoxicity using chemical structure and in vitro assay data.
Ye L; Ngan DK; Xu T; Liu Z; Zhao J; Sakamuru S; Zhang L; Zhao T; Xia M; Simeonov A; Huang R
Toxicol Appl Pharmacol; 2022 Nov; 454():116250. PubMed ID: 36150479
[TBL] [Abstract][Full Text] [Related]
27. Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes.
Ogimura E; Sekine S; Horie T
Biochem Biophys Res Commun; 2011 Dec; 416(3-4):313-7. PubMed ID: 22108051
[TBL] [Abstract][Full Text] [Related]
28. Models of Idiosyncratic Drug-Induced Liver Injury.
Yokoi T; Oda S
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():247-268. PubMed ID: 32976738
[TBL] [Abstract][Full Text] [Related]
29. Insights into mechanisms and severity of drug-induced liver injury via computational systems toxicology approach.
Peng Y; Wu Z; Yang H; Cai Y; Liu G; Li W; Tang Y
Toxicol Lett; 2019 Sep; 312():22-33. PubMed ID: 31063831
[TBL] [Abstract][Full Text] [Related]
30. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria.
Porceddu M; Buron N; Roussel C; Labbe G; Fromenty B; Borgne-Sanchez A
Toxicol Sci; 2012 Oct; 129(2):332-45. PubMed ID: 22987451
[TBL] [Abstract][Full Text] [Related]
31. A human liver organoid screening platform for DILI risk prediction.
Zhang CJ; Meyer SR; O'Meara MJ; Huang S; Capeling MM; Ferrer-Torres D; Childs CJ; Spence JR; Fontana RJ; Sexton JZ
J Hepatol; 2023 May; 78(5):998-1006. PubMed ID: 36738840
[TBL] [Abstract][Full Text] [Related]
32. In Silico Prediction of Drug-Induced Liver Injury Based on Ensemble Classifier Method.
Wang Y; Xiao Q; Chen P; Wang B
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443562
[TBL] [Abstract][Full Text] [Related]
33. Development of binary classification models for assessment of drug-induced liver injury in humans using a large set of FDA-approved drugs.
Zhang H; Zhang HR; Hu ML; Qi HZ
J Pharmacol Toxicol Methods; 2022; 116():107185. PubMed ID: 35623583
[TBL] [Abstract][Full Text] [Related]
34. Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
Schadt S; Simon S; Kustermann S; Boess F; McGinnis C; Brink A; Lieven R; Fowler S; Youdim K; Ullah M; Marschmann M; Zihlmann C; Siegrist YM; Cascais AC; Di Lenarda E; Durr E; Schaub N; Ang X; Starke V; Singer T; Alvarez-Sanchez R; Roth AB; Schuler F; Funk C
Toxicol In Vitro; 2015 Dec; 30(1 Pt B):429-37. PubMed ID: 26407524
[TBL] [Abstract][Full Text] [Related]
35. Integrating adverse outcome pathways (AOPs) and high throughput in vitro assays for better risk evaluations, a study with drug-induced liver injury (DILI).
Khadka KK; Chen M; Liu Z; Tong W; Wang D
ALTEX; 2020; 37(2):187-196. PubMed ID: 31707421
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse.
Zhang J; He K; Cai L; Chen YC; Yang Y; Shi Q; Woolf TF; Ge W; Guo L; Borlak J; Tong W
Chem Biol Interact; 2016 Aug; 255():45-54. PubMed ID: 27000539
[TBL] [Abstract][Full Text] [Related]
37. Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes.
Quintás G; Martínez-Sena T; Conde I; Pareja Ibars E; Kleinjans J; Castell JV
Arch Toxicol; 2021 Sep; 95(9):3049-3062. PubMed ID: 34274980
[TBL] [Abstract][Full Text] [Related]
38. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.
Weaver RJ; Blomme EA; Chadwick AE; Copple IM; Gerets HHJ; Goldring CE; Guillouzo A; Hewitt PG; Ingelman-Sundberg M; Jensen KG; Juhila S; Klingmüller U; Labbe G; Liguori MJ; Lovatt CA; Morgan P; Naisbitt DJ; Pieters RHH; Snoeys J; van de Water B; Williams DP; Park BK
Nat Rev Drug Discov; 2020 Feb; 19(2):131-148. PubMed ID: 31748707
[TBL] [Abstract][Full Text] [Related]
39. Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury.
Xu J; Oda S; Yokoi T
Toxicol In Vitro; 2018 Apr; 48():286-301. PubMed ID: 29407385
[TBL] [Abstract][Full Text] [Related]
40. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI.
Howell BA; Yang Y; Kumar R; Woodhead JL; Harrill AH; Clewell HJ; Andersen ME; Siler SQ; Watkins PB
J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):527-41. PubMed ID: 22875368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
